Brief: GSK Says cUTI Oral Antibiotic Tebipenem Approved By US FDA
17/06/2026 16:10
BRIEF-GSK Says cUTI Oral Antibiotic Tebipenem Approved By US FDA June 17 (Reuters) - GSK plc GSK.L:
GSK PLC - CUTI ORAL ANTIBIOTIC TEBIPENEM APPROVED BY US FDA
GSK - TEBIPENEM PIVOXIL EXPECTED TO BE AVAILABLE IN US BY END OF 2026
Source text: ID:nRSQ7248Ia
Further company coverage: GSK.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on GSK
See all newsFactbox: Major deals involving US drugmakers and biotechs over the past decade
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)
AbbVie strikes $10.9 billion deal for Apogee Therapeutics
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)
Brief: GSK Says cUTI Oral Antibiotic Tebipenem Approved By US FDA